Vanguard Group Inc. Has $195.49 Million Holdings in Summit Therapeutics PLC $SMMT

Vanguard Group Inc. lowered its position in shares of Summit Therapeutics PLC (NASDAQ:SMMT) by 1.8% during the fourth quarter, Holdings Channel reports. The fund owned 11,177,220 shares of the company’s stock after selling 202,508 shares during the quarter. Vanguard Group Inc.’s holdings in Summit Therapeutics were worth $195,490,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in SMMT. AQR Capital Management LLC raised its holdings in shares of Summit Therapeutics by 5.0% during the first quarter. AQR Capital Management LLC now owns 65,623 shares of the company’s stock valued at $1,266,000 after acquiring an additional 3,134 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Summit Therapeutics by 1.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 65,411 shares of the company’s stock valued at $1,273,000 after acquiring an additional 694 shares during the period. Creative Planning raised its holdings in shares of Summit Therapeutics by 6.7% during the second quarter. Creative Planning now owns 21,390 shares of the company’s stock valued at $455,000 after acquiring an additional 1,336 shares during the period. Legal & General Group Plc increased its stake in Summit Therapeutics by 33.8% in the 2nd quarter. Legal & General Group Plc now owns 26,367 shares of the company’s stock valued at $561,000 after buying an additional 6,662 shares during the period. Finally, Quantbot Technologies LP acquired a new position in Summit Therapeutics in the 2nd quarter valued at approximately $132,000. Institutional investors and hedge funds own 4.61% of the company’s stock.

Summit Therapeutics News Summary

Here are the key news stories impacting Summit Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $1.05 from $1.26, implying improved earnings expectations. Summit Therapeutics stock page
• Positive Sentiment: The firm also lifted quarterly forecasts for Q2 2026 to -$0.26 from -$0.31 and Q3 2026 to -$0.27 from -$0.32, which can be viewed as a modest improvement in outlook. Summit Therapeutics stock page
• Neutral Sentiment: HC Wainwright initiated or reiterated estimates for later periods, including FY2027 EPS of -$1.09 and quarterly losses around $0.27-$0.28, reinforcing that the company is still expected to remain unprofitable. Summit Therapeutics stock page
• Neutral Sentiment: The analyst maintained a Buy rating, which supports sentiment, but this was not a fresh upgrade. Summit Therapeutics stock page

Analyst Upgrades and Downgrades

Several research analysts have weighed in on SMMT shares. Citigroup started coverage on shares of Summit Therapeutics in a research note on Wednesday, April 8th. They issued a “buy” rating on the stock. Truist Financial upgraded shares of Summit Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Wall Street Zen upgraded shares of Summit Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday. Weiss Ratings restated a “sell (d-)” rating on shares of Summit Therapeutics in a research note on Tuesday, April 21st. Finally, Stifel Nicolaus assumed coverage on shares of Summit Therapeutics in a research note on Wednesday, April 8th. They set a “buy” rating and a $45.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $27.58.

Summit Therapeutics Price Performance

Shares of SMMT opened at $18.08 on Monday. Summit Therapeutics PLC has a 12 month low of $13.83 and a 12 month high of $30.98. The company’s fifty day moving average is $18.52 and its 200-day moving average is $17.71. The firm has a market cap of $14.03 billion, a price-to-earnings ratio of -11.30 and a beta of -1.25.

Summit Therapeutics (NASDAQ:SMMT) last posted its earnings results on Thursday, April 30th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.03. As a group, research analysts predict that Summit Therapeutics PLC will post -1.17 earnings per share for the current fiscal year.

About Summit Therapeutics

Summit Therapeutics plc is a clinical?stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life?threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.